Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.

Michela Del PreteFrançois-Alexandre ButeauJean-Mathieu Beauregard

Published in: European journal of nuclear medicine and molecular imaging (2017)

By standardizing the renal absorbed dose delivered during the induction course, P-PRRT has the potential to significantly increase tumour absorbed dose, thus to augment the therapeutic benefit while limiting toxicity.

Keyphrases

oxidative stress
mesenchymal stem cells
human health
binding protein
climate change